IFNG and neoplasm: An analysis of biomarkers correlated with response in these patients showed the following: MAPK pathway genomic alterations at baseline did not affect treatment benefit or clinical outcome; an IFN-γ gene expression signature higher than the median was prognostic for prolonged RFS in both treatment groups; and low tumor mutational burden was associated with longer RFS in the group of patients treated with dabrafenib and trametinib [60].